The latest news, features, and spotlights from Alumni Ventures Group

Most Recent Posts

OLIO: Sharing Food to Reduce Waste
October 20, 2021

Alumni Ventures portfolio company OLIO offers a food-sharing mobile application that seeks to reduce waste in homes and local communities. The app allows neighbors to connect and share food and rallies volunteers (branded as Food Waste Heroes) to collect and list surplus food from local businesses for pickup. Common listings include food nearing sell-by dates, spare homegrown vegetables, unused groceries, and nonfood household items.

Blue Note Therapeutics: Better Care for Cancer Patients
October 19, 2021

Dedicated to serving patients suffering from cancer-related distress, Alumni Ventures portfolio company Blue Note Therapeutics is on a mission to ease the burdens of cancer through Prescription Digital Therapeutics (PDT). The company’s software is designed to improve outcomes through decreased psychological distress, strengthened immune function, and improved treatment adherence.

Seed Investing Trends in Emerging Sectors
October 18, 2021

Promising seed-stage opportunities exist where talented innovators intersect with cutting-edge technology. Our team monitors a diverse spectrum of industries and verticals to identify nascent companies as they emerge. We explore seed investing trends in high-potential sectors and highlight some examples from our portfolio.

Arcadia: Cleaner Energy, Reduced Costs
October 6, 2021

Founded in 2014, Alumni Ventures portfolio company Arcadia has developed a clean energy tech platform that provides individuals and organizations with access to solar power and greater transparency into their energy usage. The company’s platform integrates with over 125 utilities, manages 4.5 terawatt-hours of residential energy demand, and is the largest community solar platform in the U.S.

Veralox Therapeutics: Developing Improved Treatment Options
October 5, 2021

Founded by a trio of life science veterans, Alumni Ventures portfolio company Veralox Therapeutics is building a robust pipeline of therapeutics targeting 12-lipoxygenase (12-LOX), which is associated with the onset and progression of a range of serious diseases like HIT.

Ready To Join The AVG Community?

Featured Posts